Total pharma venture financing deals for January 2019 worth $1.43bn were announced in the United States, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 17.2% over the previous month and a rise of 10.1% when compared with the last 12-month average of $1.3bn.
The United States held a 71.7% share of the global pharma venture financing deal value that touched $1.99bn in January 2019.
In terms of deal activity, the United States recorded 47 deals during January 2019, marking a decrease of 13% over the previous month and over the 12-month average.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPharma venture financing deals for January 2019: Top deals
The top five pharma venture financing deals accounted for 44.01% of the overall value in January 2019.
The combined value of the top five pharma venture financing deals stood at $629.2m, against the overall value of $1.43bn recorded for the month. The top announced pharma venture financing deal tracked by GlobalData in January 2019 was American International Group, Hercules Capital, Kohlberg Kravis Roberts & Co, Perceptive Advisors, Sequoia Capital Operations, and Viking Global Investors’ $299.2m venture financing of BridgeBio Pharma.
In second place was CMB International Capital’s venture financing of Apollomics for $100m and in third place was Deerfield Management and GV Management Co’s $85m venture financing of Schrodinger.
New Enterprise Associates, Nextech Invest, Perceptive Advisors, RA Capital Management, and Invus Group’s $85m venture financing of Black Diamond Therapeutics and Alexandria Venture Investments, EcoR1 Capital, Polaris Partners, and Samsara BioCapital’s venture financing of Dewpoint Therapeutics for $60m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
Verdict’s parent company GlobalData plc provides business information to 4,000 of the world’s largest companies.
